CC-5013 in Treating Patients With Recurrent Glioma (NCT00036894) | Clinical Trial Compass
CompletedPhase 1
CC-5013 in Treating Patients With Recurrent Glioma
United StatesStarted 2002-03
Plain-language summary
RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor.
PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* One of the following:
* Histologically confirmed high-grade glioma
* Glioblastoma multiforme
* Gliosarcoma
* Anaplastic astrocytoma
* Anaplastic oligodendroglioma
* Anaplastic mixed oligoastrocytoma
* Malignant glioma/astrocytoma, not otherwise specified
* Meningioma
* Hemangioblastoma
* Ependymoma
* Primitive neuroectodermal tumors
* Hemangiopericytoma
* Progressive glioma
* Clinically and radiographically diagnosed brain stem glioma
* Progressive or recurrent disease as determined by CT scan or MRI
* Biopsy allowed for prior recent (i.e., within the past 12 weeks) resection of recurrent or progressive tumor
* Must have failed prior radiotherapy
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* Karnofsky 60-100%
Life expectancy:
* More than 8 weeks
Hematopoietic:
* WBC at least 2,300/mm\^3
* Platelet count at least 90,000/mm\^3
* Hemoglobin at least 8 g/dL (transfusions allowed)
Hepatic:
* Bilirubin less than 3 times upper limit of normal (ULN)
* SGOT less than 3 times ULN
* No significant active hepatic disease
Renal:
* Creatinine less than 2.0 mg/dL OR
* Creatinine clearance at least 60 mL/min
* No significant active renal disease
Cardiovascular:
* No significant active cardiac disease
Other:
* No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
* No significant active psychiatric disease
* Not pregn…